CORCEPT THERAPEUTICS INC
CORTNasdaq
$90.52
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↑ +24.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.5B
Enterprise Value
$9.1B
P/E
258.6
P/S
12.3
P/B
14.8
EV/EBITDA
—
PEG
—
FCF Yield
1.3%
Dividend Yield
—
Revenue (TTM)
$769.1M
Net Income (TTM)
$47.3M
Free Cash Flow (TTM)
$120.1M
Gross Margin
—
Operating Margin
-1.1%
Net Margin
6.2%
ROE
7.4%
ROIC
-2.7%
Debt / Equity
—
Net Cash
$338.2M
Return 1Y
+23.8%
Company profile
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the. treatment of hyperglycemia secondary to hypercortisolism in adult patients with. endogenous Cushing's syndrome.
- CEO
- Joseph K. Belanoff
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 300
- Headquarters
- California
- Website
- corcept.com
Management & directors
- Mokari AtabakChief Financial Officer
- Guyer WilliamChief Development Officer
- Maduck SeanSee Remarks
- Lyon Joseph DouglasSee Remarks
- Robb Gary CharlesChief Business Officer
- Belanoff Joseph KChief Executive Officer
- Hunt HazelChief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
CORT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$164.9M↑ +4.9%
Diluted EPS-$0.30↓ -276.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $353.9M | $366.0M | $401.9M | $482.4M | $675.0M | $761.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $128.2M | $124.5M | $112.6M | $107.3M | $137.0M | $44.8M |
| Net income | $106.0M | $112.5M | $101.4M | $106.1M | $141.2M | $99.7M |
| Diluted EPS | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 |
| Operating cash flow | $152.0M | $167.9M | $120.3M | $126.7M | $198.3M | $142.0M |
| Free cash flow | $150.7M | $167.4M | $119.9M | $126.5M | $196.1M | $141.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 36.2% | 34.0% | 28.0% | 22.2% | 20.3% | 5.9% |
| Net margin | 30.0% | 30.7% | 25.2% | 22.0% | 20.9% | 13.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $163.8M | $182.5M | $181.9M | $157.2M | $194.4M | $207.6M | $202.1M | $164.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $35.6M | $46.6M | $25.3M | $3.4M | $26.7M | $10.2M | $4.5M | -$49.6M |
| Net income | $35.5M | $47.2M | $30.7M | $20.5M | $35.1M | $19.7M | $24.3M | -$31.8M |
| Diluted EPS | $0.32 | $0.41 | $0.25 | $0.17 | $0.29 | $0.16 | $0.20 | -$0.30 |
| Operating cash flow | $41.2M | $73.3M | $60.1M | $4.8M | $44.3M | $54.5M | $38.4M | -$16.8M |
| Free cash flow | $40.8M | $71.7M | $59.9M | $4.7M | $44.2M | $54.5M | $38.4M | -$17.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 21.7% | 25.5% | 13.9% | 2.2% | 13.7% | 4.9% | 2.2% | -30.1% |
| Net margin | 21.7% | 25.9% | 16.9% | 13.1% | 18.1% | 9.5% | 12.0% | -19.3% |
Company news
Jul 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Mokari Atabak· Chief Financial Officer | Sale | 28,460 | $87.89 | $2.5M | filing |
| 2026-07-15 | Mokari Atabak· Chief Financial Officer | Sale | 7,919 | $86.78 | $687,179.14 | filing |
| 2026-07-15 | Mokari Atabak· Chief Financial Officer | Option exercise | 24,167 | $23.06 | $557,291.02 | filing |
| 2026-07-15 | WILSON JAMES N | Sale | 3,969 | $87.74 | $348,222.60 | filing |
| 2026-07-15 | Mokari Atabak· Chief Financial Officer | Sale | 3,520 | $88.30 | $310,821.63 | filing |
| 2026-07-15 | Mokari Atabak· Chief Financial Officer | Option exercise | 15,833 | $19.26 | $304,943.58 | filing |
| 2026-07-15 | WILSON JAMES N | Sale | 2,974 | $88.81 | $264,122.43 | filing |
| 2026-07-15 | WILSON JAMES N | Sale | 1,978 | $89.49 | $177,007.46 | filing |
| 2026-07-15 | WILSON JAMES N | Sale | 1,079 | $86.78 | $93,633.14 | filing |
| 2026-07-15 | Mokari Atabak· Chief Financial Officer | Sale | 101 | $89.43 | $9,032.25 | filing |
| 2026-07-07 | Guyer William· Chief Development Officer | Sale | 19,048 | $93.11 | $1.8M | filing |
| 2026-07-07 | Guyer William· Chief Development Officer | Option exercise | 20,000 | $21.65 | $433,000.00 | filing |
| 2026-07-07 | Guyer William· Chief Development Officer | Sale | 952 | $93.54 | $89,048.46 | filing |
| 2026-07-01 | Maduck Sean· See Remarks | Sale | 11,175 | $89.31 | $998,032.55 | filing |
| 2026-07-01 | Maduck Sean· See Remarks | Sale | 11,024 | $87.33 | $962,779.94 | filing |
| 2026-07-01 | Maduck Sean· See Remarks | Sale | 2,801 | $88.51 | $247,924.07 | filing |
| 2026-07-01 | Maduck Sean· See Remarks | Option exercise | 25,000 | $8.27 | $206,750.00 | filing |
| 2026-06-17 | MAHONEY DAVID L | Sale | 20,000 | $84.53 | $1.7M | filing |
| 2026-06-16 | WILSON JAMES N | Sale | 5,823 | $83.57 | $486,632.77 | filing |
| 2026-06-16 | WILSON JAMES N | Sale | 4,177 | $82.69 | $345,416.18 | filing |
| 2026-06-15 | Mokari Atabak· Chief Financial Officer | Sale | 19,483 | $81.81 | $1.6M | filing |
| 2026-06-15 | Mokari Atabak· Chief Financial Officer | Sale | 11,081 | $80.94 | $896,922.73 | filing |
| 2026-06-15 | Mokari Atabak· Chief Financial Officer | Option exercise | 40,000 | $19.26 | $770,400.00 | filing |
| 2026-06-15 | Mokari Atabak· Chief Financial Officer | Sale | 9,434 | $80.02 | $754,923.77 | filing |
| 2026-06-15 | Mokari Atabak· Chief Financial Officer | Sale | 2 | $82.45 | $164.90 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.